Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002373 | 0.90 | ACE (0.53) | F2STAT6C5AR1ACEOPRM1 | |
| SCHEMBL5969903 | 0.90 | ACE (0.53) | F2STAT6C5AR1ACEOPRM1 | |
| SCHEMBL5969907 | 0.89 | F2 (0.52) | F2STAT6C5AR1ACEOPRM1 | |
| SCHEMBL8953877 | 0.86 | C5AR1 (0.55) | F2C5AR1APLNRREN | |
| SCHEMBL9642162 | 0.86 | NTSR2 (0.43) | F2C5AR1OPRM1OPRK1APLNR | |
| SCHEMBL10622567 | 0.86 | C5AR1 (0.54) | F2C5AR1APLNRREN | |
| SCHEMBL8953791 | 0.86 | C5AR1 (0.52) | F2C5AR1ACEAPLNRREN | |
| SCHEMBL2814077 | 0.85 | SLC15A2 (0.47) | — | |
| SCHEMBL2354522 | 0.85 | SLC15A2 (0.46) | — | |
| SCHEMBL2354514 | 0.85 | SLC15A2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7186687-B2 | Compositions and methods for treatment of Psoriasis | PROCYTE CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | F2 3775/4885STAT6 2852/4885C5AR1 3034/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | F2 3573/4885STAT6 1913/4885C5AR1 2439/4885 |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | F2 847/4885STAT6 738/4885C5AR1 238/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | F2 1511/4885STAT6 2390/4885C5AR1 1684/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | F2 603/4885STAT6 18/4885C5AR1 277/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | F2 3775/4885STAT6 2852/4885C5AR1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.